Kevin Bitterman Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Kevin Bitterman.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Kevin Bitterman. Kevin Bitterman is a Director in GENOCEA BIOSCIENCES, INC. ($GNCA) and a Director in Editas Medicine, Inc. ($EDIT) and a Director in Akero Therapeutics, Inc. ($AKRO).
Address: C/O POLARIS VENTURE PARTNERS 1000 WINTER STREET, SUITE 3350 WALTHAM 02451 MA
Companies in which Kevin Bitterman is an Insider
Akero Therapeutics, Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Kevin Bitterman: Director
Holdings: 11,780 shares
Latest Transaction: Oct 14 2020
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Editas Medicine, Inc.
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Kevin Bitterman: Director
Holdings: 2,797,144 shares
Current Value: $51,914,993
Latest Transaction: Jun 19 2017
$EDIT Market Capitalization: $636.78M
$EDIT Previous Close: $18.56
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
GENOCEA BIOSCIENCES, INC.
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Kevin Bitterman: Director
Holdings: 2,128,678 shares
Current Value: $9,600,338
Latest Transaction: Jun 07 2016
$GNCA Market Capitalization: $129.13M
$GNCA Previous Close: $4.51
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Latest Insider Trading Transactions of Kevin Bitterman
Sentiment: All, AKRO, EDIT, GNCA
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 14 2020 | AKRO | Akero Therapeutics ... | Bitterman Kevin | Director | Sell | S | 28.93 | 13,000 | 376,090 | 11,780 | 24.8 K to 11.8 K (-52.46 %) |
| Jun 02 2020 | AKRO | Akero Therapeutics ... | Bitterman Kevin | Director | Option Exercise | A | 25.20 | 13,000 | 327,600 | 13,000 | |
| Nov 12 2019 | AKRO | Akero Therapeutics ... | Bitterman Kevin | Director | Option Exercise | A | 19.97 | 26,000 | 519,220 | 26,000 | |
| Jun 25 2019 | AKRO | Akero Therapeutics ... | Bitterman Kevin | Director | Option Exercise | C | 0.00 | 722,737 | 0 | 0 | |
| Jun 25 2019 | AKRO | Akero Therapeutics ... | Bitterman Kevin | Director | Option Exercise | C | 0.00 | 10,666,667 | 0 | 0 | |
| Jun 25 2019 | AKRO | Akero Therapeutics ... | Bitterman Kevin | Director | Buy | P | 16.00 | 270,000 | 4,320,000 | 505,099 | 235.1 K to 505.1 K (+114.85 %) |
| Jun 25 2019 | AKRO | Akero Therapeutics ... | Bitterman Kevin | Director | Buy | C | 0.00 | 235,099 | 0 | 235,099 | 0 to 235.1 K |